Analyst Price Target Update on BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX): 7 analysts have set the short term price target of BioCryst Pharmaceuticals (NASDAQ:BCRX) at $7.14. The standard deviation of short term price target has been estimated at $4.78, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 16 and $2 respectively.

Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, The officer (Senior Vice President and CFO), of Biocryst Pharmaceuticals Inc, Staab Thomas R Ii had unloaded 3,052 shares at $10.86 per share in a transaction on December 21, 2015. The total value of transaction was $33,145. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

BioCryst Pharmaceuticals (NASDAQ:BCRX) witnessed a volatile trading activity on Monday and eventually ended flat at 0% or 0 points without letting the bulls or bears take much advantage. The trading began at $3.02 and reached the intraday high at $3.14. The bulls started the profit booking and pushed the shares to intraday low of $3.0001. The trading session was marked by a volume range of 1,003,489 shares exchanging hands. The 52-week high of the shares is $16.83 and the 52-week low is $1.63. The market cap of the company stands at $225 million and there are 73,692,799 shares in public circulation.

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its products include RAPIVAB, BCX4161, BCX7353 and other second generation HAE compounds, BCX4430 and Forodesine. Peramivir is an intravenous neuraminidase inhibitor approved in multiple countries for the treatment of patients with influenza, in the United States as RAPIVAB, in Japan as RAPIACTA and in Korea as PERAMIFLU. BCX4161 is the Companys Hereditary Angioedema (HAE) product candidate. BCX7353 is a plasma kallikrein inhibitor. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.